Infectious Diseases

Regeneron/Sanofi’s PD-1 drug candidate will be tested with ISA’s HPV immunotherapy Regeneron and Sanofi’s PD-1 candidate cemiplimab is paired with Dutch biotech ISA Pharma’s human papillomavirus (HPV) targeting drug for testing. The new drug is competing to become the sixth PD-1/PD-L1 drug on the market. Joined with ISA’s ISA101 vaccine candidate to cope with HPV-related cancers like cervical and head-and-neck cancer. Zika targeting drugs and vaccines development will be improved through new ideas Scientists from Stanford have devised an approach that to fight Zika through a completely new approach by targeting a certain protein in the host cell further preventing the ...